Flare changes after intravitreal injection of ocriplasmin in symptomatic vitreomacular traction syndrome.

Vittorio PiraniPaolo PelliccioniClaudia CesariGiulia CarrozziEdoardo CavalleroCesare Mariotti

Published in: Japanese journal of ophthalmology (2019)

Our study shows that intravitreal injection of ocriplasmin can be a safe and effective approach to treat symptomatic VMT syndrome in selected patients.

Keyphrases

end stage renal disease
vascular endothelial growth factor
chronic kidney disease
ejection fraction
newly diagnosed
diabetic retinopathy
prognostic factors
ultrasound guided
age related macular degeneration
peritoneal dialysis